Jon Wigginton
Direttore/Membro del Consiglio presso SUTRO BIOPHARMA, INC.
Patrimonio netto: - $ in data 31/05/2024
Posizioni attive di Jon Wigginton
Società | Posizione | Inizio | Fine |
---|---|---|---|
SUTRO BIOPHARMA, INC. | Direttore/Membro del Consiglio | 30/11/2020 | - |
Independent Dir/Board Member | 30/11/2020 | - | |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Direttore/Membro del Consiglio | 15/10/2020 | - |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Direttore/Membro del Consiglio | - | - |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Direttore Tecnico/Scientifico/R&S | - | - |
Storia della carriera di Jon Wigginton
Precedenti posizioni note di Jon Wigginton
Società | Posizione | Inizio | Fine |
---|---|---|---|
CULLINAN THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/04/2020 | 01/08/2022 |
Corporate Officer/Principal | 01/04/2020 | 01/08/2022 | |
CHECKMATE PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 30/01/2022 | 31/05/2022 |
Independent Dir/Board Member | 30/01/2022 | 31/05/2022 | |
MACROGENICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2016 | 27/03/2020 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/10/2008 | - |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Corporate Officer/Principal | 01/05/2006 | - |
░░░░░░ ░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░ ░░░░░░░░░░░░░ ░░ ░░░░░░ | ░░░░░░░░░ | - | - |
░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formazione di Jon Wigginton
University of Michigan | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 13 |
Svizzera | 2 |
Posizioni
Chief Tech/Sci/R&D Officer | 4 |
Corporate Officer/Principal | 4 |
Director/Board Member | 4 |
Settori
Health Technology | 10 |
Consumer Services | 2 |
Government | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
SUTRO BIOPHARMA, INC. | Health Technology |
MACROGENICS, INC. | Health Technology |
CULLINAN THERAPEUTICS, INC. | Health Technology |
Aziende private | 8 |
---|---|
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Health Technology |
Center for Cancer Research | Government |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Bright Peak Therapeutics AG
Bright Peak Therapeutics AG BiotechnologyHealth Technology Bright Peak Therapeutics AG engages in the development of engineered cytokines for immuno-oncology indications. The company is headquartered in Basel, Switzerland. | Health Technology |
Society For Immunotherapy of Cancer
Society For Immunotherapy of Cancer Miscellaneous Commercial ServicesCommercial Services The Society for Immunotherapy of Cancer (SITC) is an organization that advances the science, development, and application of immunotherapy to improve cancer patient outcomes. The non-profit company is based in Milwaukee, WI. SITC conducts policy and advocacy efforts on behalf of its members and the field. The Journal for Immunotherapy of Cancer (JITC) is the official open access, peer-reviewed online journal of SITC, featuring original research articles, literature reviews, position papers, and discussions on all aspects of tumor immunology and cancer immunotherapy. SITC also created a conceptual framework for potential value in phase III studies evaluating immunotherapy combinations. | Commercial Services |
Kalivir Immunotherapeutics, Inc.
Kalivir Immunotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Kalivir Immunotherapeutics, Inc. is a privately held biotech company based in Pittsburgh, PA. The company is focused on developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs. Kalivir has developed a unique virus-based platform, enhanced template "vet" platform, that can generate potent novel oncolytic viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. The company has separate collaborations with Roche and Astellas Pharma to design and generate novel oncolytic viruses derived from the vet™ platform. Kalivir is currently advancing multiple therapeutic candidates toward the clinic. The CEO of the company is Helena H. Chaye. | Health Technology |
- Borsa valori
- Insiders
- Jon Wigginton
- Esperienza